Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PERRIGO COMPANY PLC

(PRGO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Perrigo : To Present Virtually At Upcoming Consumer Investor Conferences

05/21/2021 | 08:31am EDT

DUBLIN, May 21, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that that President and CEO, Murray S. Kessler and CFO, Ray Silcock are scheduled to participate in investor meetings at the Barclays Consumer Spring Symposium on Tuesday, May 25.  

Also, President and CEO, Murray S. Kessler is scheduled to present at the Oppenheimer 21st Annual Consumer Growth and Ecommerce Conference at 9:05 AM (EDT) on Wednesday, June 16.   

Lastly, President and CEO, Murray S. Kessler and CFO, Ray Silcock are scheduled to present at the Evercore ISI Consumer & Retail Summit at 2:45 PM (EDT) on Thursday, June 17.   

Interested parties can access the Oppenheimer and Evercore ISI presentation webcasts on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.

About Perrigo

Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer 'own brand' labels. Additionally, Perrigo is a Top 10 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. Visit Perrigo online at www.perrigo.com

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "forecast," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and supply chain impacts on the Company's business; general economic, credit, and market conditions; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment (the "NoA") issued by the Irish tax authority and the draft and final Notices of Proposed Assessment ("NOPAs") issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NoA and the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency exchange rates and interest rates; the consummation and success of the sale of the Rx business, including the ability to achieve the expected benefits thereof, the risk that any required regulatory approvals will not be received or obtained or other closing conditions may not be satisfied within the expected time frame or at all and potential costs or liabilities incurred or retained in connection with the proposed transaction that may exceed the Company's estimates or adversely affect the Company's business or operations; the consummation and success of other announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to our appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2020, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/perrigo-to-present-virtually-at-upcoming-consumer-investor-conferences-301296875.html

SOURCE Perrigo Company plc


ę PRNewswire 2021
All news about PERRIGO COMPANY PLC
07/28PERRIGO : To Release Second Quarter 2021 Financial Results On August 11, 2021
PR
07/22AMERICAN VIRTUAL CLOUD TECHNOLOGIES : Reshuffles Board, Senior Management, Share..
MT
07/14PERRIGO : Thinking about trading options or stock in Apple, Boeing, Perrigo, Mas..
PR
07/13PERRIGO CO PLC : Regulation FD Disclosure (form 8-K)
AQ
07/12PERRIGO CO PLC : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
07/06PERRIGO : Completes Generic Rx Pharmaceuticals Business Sale For $1.55 Billion
MT
07/06PERRIGO : Completes Divestiture Of Generic Rx Business For $1.55 Billion
PR
07/06Altaris Capital Partners, LLC completed the acquisition of Generic Rx Pharmac..
CI
06/21U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel d..
RE
06/21U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel d..
RE
More news